Semaglutide works through steady-state concentrations, not higher peak levels
As of June 2025, the branded version of liraglutide, Saxenda, generated $165 million in annual sales alone, and the market for GLP-1s could be set to hit over $126 billion in sales by 2029
Compounded semaglutide is a prescription drug made by state-licensed or FDA-registered pharmacies, but it is not FDA approved [5]
Good practice for all reconstituted vials includes: Labelling each vial with the date and time of reconstitution, the diluent used, the concentration, the assigned beyond-use date (as per sponsor/manufacturer data), and the initials of the person who prepared it
Article PubMed Google Scholar Conte, C., Hall, K
Twelve studies were rated as high risk, including all those that included or recruited participants with binge eating disorder, while the remaining studies were rated as having some concerns